

4/6/04

kam - 09 / 847048

Page 1

=> fil reg

FILE 'REGISTRY' ENTERED AT 10:53:29 ON 06 APR 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 4 APR 2004 HIGHEST RN 671180-42-0  
DICTIONARY FILE UPDATES: 4 APR 2004 HIGHEST RN 671180-42-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004


Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more  
information enter HELP PROP at an arrow prompt in the file or refer  
to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d sta que l29

L27 STR



VAR G1=CHO/N

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 5

STEREO ATTRIBUTES: NONE

L29 9849 SEA FILE=REGISTRY SSS FUL L27


100.0% PROCESSED 122800 ITERATIONS

9849 ANSWERS

SEARCH TIME: 00.00.05

=> d que l30

L12	3379	SEA	FILE=REGISTRY	ABB=ON	PLU=ON	23290/RID
L17	3476	SEA	FILE=REGISTRY	ABB=ON	PLU=ON	L12 OR ?VANCOMYCIN?/CNS
L18	97	SEA	FILE=REGISTRY	ABB=ON	PLU=ON	L17 NOT L12
L19	96	SEA	FILE=REGISTRY	ABB=ON	PLU=ON	L18 NOT CCS/CI
L20	40	SEA	FILE=REGISTRY	ABB=ON	PLU=ON	L19 NOT SQL/FA
L21	36	SEA	FILE=REGISTRY	ABB=ON	PLU=ON	L20 NOT ?TRANSFERASE?/CNS
L22	61	SEA	FILE=REGISTRY	ABB=ON	PLU=ON	L18 NOT L21
L23	3415	SEA	FILE=REGISTRY	ABB=ON	PLU=ON	L17 NOT L22
L27						STR




VAR G1=CHO/N  
 NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 5

STEREO ATTRIBUTES: NONE  
 L29 9849 SEA FILE=REGISTRY SSS FUL L27  
 L30 0 SEA FILE=REGISTRY ABB=ON PLU=ON L29 AND L23

=> d que l31  
 L27 STR




VAR G1=CHO/N  
 NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 5

STEREO ATTRIBUTES: NONE  
 L29 9849 SEA FILE=REGISTRY SSS FUL L27  
 L31 0 SEA FILE=REGISTRY ABB=ON PLU=ON L29 AND ?VANCOMYCIN?/CNS

=> d sta que l46  
 L27 STR




VAR G1=CHO/N  
 NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 5

STEREO ATTRIBUTES: NONE

L29 9849 SEA FILE=REGISTRY SSS FUL L27

L41 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 5

STEREO ATTRIBUTES: NONE

L42 90 SEA FILE=REGISTRY SUB=L29 SSS FUL L41

L43 32 SEA FILE=REGISTRY ABB=ON PLU=ON L42 AND (C18H34OS2 OR C7H12OS2 OR C8H14O2S OR C13H16O2S OR C7H10O2S OR C5H8O2S OR C8H14O2S OR C9H16O2S OR C4H6O2S OR C12H12O2S OR C13H22O2S OR C6H10O2S OR C11H20O2S OR C11H12O2S OR C9H16O2S OR C12H14O2S OR C8H14O2S OR C13H24O2S OR C7H10O2S OR C5H6O2S OR C10H8O2S OR C17H16O2S)


L44 58 SEA FILE=REGISTRY ABB=ON PLU=ON L42 NOT L43

L45 2 SEA FILE=REGISTRY ABB=ON PLU=ON L44 AND (C18H34O2S OR C7H12O2S)

L46 34 SEA FILE=REGISTRY ABB=ON PLU=ON (L43 OR L45)

=> d sta que 156

L27 STR



VAR G1=CHO/N

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 5

STEREO ATTRIBUTES: NONE

L29 9849 SEA FILE=REGISTRY SSS FUL L27

L54 STR



VAR G1=NH2/7/11

VAR G2=AK/9

NODE ATTRIBUTES:

CONNECT IS M1 RC AT 2  
CONNECT IS M1 RC AT 10  
CONNECT IS M1 RC AT 12  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE  
L56 509 SEA FILE=REGISTRY SUB=L29 CSS FUL L54

100.0% PROCESSED 9780 ITERATIONS 509 ANSWERS  
SEARCH TIME: 00.00.01

=> d his

(FILE 'HOME' ENTERED AT 09:40:00 ON 06 APR 2004)  
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 09:40:16 ON 06 APR 2004

E MU Y/AU  
L1 21 S E3,E7  
E MU YONG/AU  
L2 22 S E5,E11  
L3 2 S (US20030078371 OR US20020077280)/PN OR (WO2001-US14000 OR WO2  
E ADV MED/PA,CS  
L4 2 S E5,E6  
E ADVAN MED/PA,CS  
E ADVANC MED/PA,CS  
E ADVANCED MED/PA,CS  
L5 60 S E5-E9,E65-E77  
L6 101 S L1-L5  
SEL RN  
DEL SEL

FILE 'REGISTRY' ENTERED AT 09:44:08 ON 06 APR 2004

FILE 'HCAPLUS' ENTERED AT 09:44:08 ON 06 APR 2004

SET SMARTSELECT ON  
L7 SEL L6 1- RN : 3410 TERMS  
SET SMARTSELECT OFF

FILE 'REGISTRY' ENTERED AT 09:44:12 ON 06 APR 2004

L8 3410 S L7  
L9 505 S L8 AND VANCOMY?  
L10 306 S L8 AND S/ELS  
L11 113 S L9 AND L10  
E 23290/RID  
L12 3379 S E3  
L13 505 S L8 AND L12  
L14 565 S L12 AND S/ELS  
L15 555 S L14 AND OC5/ES  
L16 10 S L14 NOT L15  
L17 3476 S L12 OR ?VANCOMYCIN?/CNS  
L18 97 S L17 NOT L12  
L19 96 S L18 NOT CCS/CI  
L20 40 S L19 NOT SQL/FA  
L21 36 S L20 NOT ?TRANSFERASE?/CNS  
L22 61 S L18 NOT L21

L23 3415 S L17 NOT L22  
L24 565 S L23 AND S/ELS  
L25 STR  
L26 36 S L25  
L27 STR L25  
L28 50 S L27  
L29 9849 S L27 FUL  
SAV TEMP L29 KAM847/A  
L30 0 S L29 AND L23  
L31 0 S L29 AND ?VANCOMYCIN?/CNS

FILE 'HCAPLUS' ENTERED AT 09:52:27 ON 06 APR 2004

L32 5597 S L23  
L33 6924 S ?VANCOMYCIN?  
L34 7296 S L32,L33  
L35 12614 S L29  
L36 7 S L34 AND L35  
L37 0 S L6 AND L36  
SEL HIT RN L36

FILE 'REGISTRY' ENTERED AT 09:54:58 ON 06 APR 2004

L38 12 S E1-E12  
L39 2 S L38 AND L23  
L40 10 S L38 AND L29  
L41 STR L27  
L42 90 S L41 FUL SUB=L29  
SAV L42 KAM847A/A  
L43 32 S L42 AND (C18H34O2S OR C7H12O2S OR C8H14O2S OR C13H16O2S OR C7  
L44 58 S L42 NOT L43  
L45 2 S L44 AND (C18H34O2S OR C7H12O2S)  
L46 34 S L43,L45  
SAV L46 KAM847B/A

FILE 'HCAPLUS' ENTERED AT 10:46:30 ON 06 APR 2004

L47 37 S L46  
L48 0 S L47 AND L6  
L49 0 S L47 AND L34  
L50 26 S L46 (L) RACT+NT/RL

FILE 'REGISTRY' ENTERED AT 10:48:05 ON 06 APR 2004

L51 STR L41  
L52 46 S L51 SAM SUB=L29  
L53 826 S L51 FUL SUB=L29  
SAV TEMP L53 KAM847C/A  
L54 STR L51  
L55 25 S L54 CSS SAM SUB=L29  
L56 509 S L54 CSS FUL SUB=L29  
SAV TEMP L56 KAM847D/A

FILE 'HCAPLUS' ENTERED AT 10:52:48 ON 06 APR 2004

L57 170 S L56  
L58 0 S L57 AND L50  
L59 0 S L57 AND L47

FILE 'REGISTRY' ENTERED AT 10:53:29 ON 06 APR 2004

=> => fil reg

FILE 'REGISTRY' ENTERED AT 11:00:45 ON 06 APR 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file

provided by InfoChem.

STRUCTURE FILE UPDATES: 4 APR 2004 HIGHEST RN 671180-42-0  
 DICTIONARY FILE UPDATES: 4 APR 2004 HIGHEST RN 671180-42-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more  
 information enter HELP PROP at an arrow prompt in the file or refer  
 to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d sta que l64

```
L12      3379 SEA FILE=REGISTRY ABB=ON  PLU=ON  23290/RID
L17      3476 SEA FILE=REGISTRY ABB=ON  PLU=ON  L12 OR ?VANCOMYCIN?/CNS
L18      97 SEA FILE=REGISTRY ABB=ON  PLU=ON  L17 NOT L12
L19      96 SEA FILE=REGISTRY ABB=ON  PLU=ON  L18 NOT CCS/CI
L20      40 SEA FILE=REGISTRY ABB=ON  PLU=ON  L19 NOT SQL/FA
L21      36 SEA FILE=REGISTRY ABB=ON  PLU=ON  L20 NOT ?TRANSFERASE?/CNS
L22      61 SEA FILE=REGISTRY ABB=ON  PLU=ON  L18 NOT L21
L23     3415 SEA FILE=REGISTRY ABB=ON  PLU=ON  L17 NOT L22
L60      STR
```

```
  6
  O
  ||
  ||
2 C---S
  3
```

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 3

STEREO ATTRIBUTES: NONE

L62 3476 SEA FILE=REGISTRY ABB=ON PLU=ON (L17 OR L23)

L64 45 SEA FILE=REGISTRY SUB=L62 SSS FUL L60

100.0% PROCESSED 45 ITERATIONS

45 ANSWERS

SEARCH TIME: 00.00.01

=> d his

(FILE 'HOME' ENTERED AT 09:40:00 ON 06 APR 2004)

SET COST OFF

FILE 'HCAPLUS' ENTERED AT 09:40:16 ON 06 APR 2004

E MU Y/AU

L1 21 S E3,E7

E MU YONG/AU

L2 22 S E5,E11

L3 2 S (US20030078371 OR US20020077280)/PN OR (WO2001-US14000 OR WO2  
 E ADV MED/PA,CS

L4 2 S E5,E6  
E ADVAN MED/PA,CS  
E ADVANC MED/PA,CS  
E ADVANCED MED/PA,CS  
L5 60 S E5-E9,E65-E77  
L6 101 S L1-L5  
SEL RN  
DEL SEL

FILE 'REGISTRY' ENTERED AT 09:44:08 ON 06 APR 2004

FILE 'HCAPLUS' ENTERED AT 09:44:08 ON 06 APR 2004

SET SMARTSELECT ON  
L7 SEL L6 1- RN : 3410 TERMS  
SET SMARTSELECT OFF

FILE 'REGISTRY' ENTERED AT 09:44:12 ON 06 APR 2004

L8 3410 S L7  
L9 505 S L8 AND VANCOMY?  
L10 306 S L8 AND S/ELS  
L11 113 S L9 AND L10  
E 23290/RID  
L12 3379 S E3  
L13 505 S L8 AND L12  
L14 565 S L12 AND S/ELS  
L15 555 S L14 AND OC5/ES  
L16 10 S L14 NOT L15  
L17 3476 S L12 OR ?VANCOMYCIN?/CNS  
L18 97 S L17 NOT L12  
L19 96 S L18 NOT CCS/CI  
L20 40 S L19 NOT SQL/FA  
L21 36 S L20 NOT ?TRANSFERASE?/CNS  
L22 61 S L18 NOT L21  
L23 3415 S L17 NOT L22  
L24 565 S L23 AND S/ELS  
L25 STR  
L26 36 S L25  
L27 STR L25  
L28 50 S L27  
L29 9849 S L27 FUL  
SAV TEMP L29 KAM847/A  
L30 0 S L29 AND L23  
L31 0 S L29 AND ?VANCOMYCIN?/CNS

FILE 'HCAPLUS' ENTERED AT 09:52:27 ON 06 APR 2004

L32 5597 S L23  
L33 6924 S ?VANCOMYCIN?  
L34 7296 S L32,L33  
L35 12614 S L29  
L36 7 S L34 AND L35  
L37 0 S L6 AND L36  
SEL HIT RN L36

FILE 'REGISTRY' ENTERED AT 09:54:58 ON 06 APR 2004

L38 12 S E1-E12  
L39 2 S L38 AND L23  
L40 10 S L38 AND L29  
L41 STR L27  
L42 90 S L41 FUL SUB=L29  
SAV L42 KAM847A/A  
L43 32 S L42 AND (C18H34O2S OR C7H12O2S OR C8H14O2S OR C13H16O2S OR C7  
L44 58 S L42 NOT L43  
L45 2 S L44 AND (C18H34O2S OR C7H12O2S)

L46 34 S L43,L45  
SAV L46 KAM847B/A

FILE 'HCAPLUS' ENTERED AT 10:46:30 ON 06 APR 2004

L47 37 S L46  
L48 0 S L47 AND L6  
L49 0 S L47 AND L34  
L50 26 S L46 (L) RACT+NT/RL

FILE 'REGISTRY' ENTERED AT 10:48:05 ON 06 APR 2004

L51 STR L41  
L52 46 S L51 SAM SUB=L29  
L53 826 S L51 FUL SUB=L29  
SAV TEMP L53 KAM847C/A  
L54 STR L51  
L55 25 S L54 CSS SAM SUB=L29  
L56 509 S L54 CSS FUL SUB=L29  
SAV TEMP L56 KAM847D/A

FILE 'HCAPLUS' ENTERED AT 10:52:48 ON 06 APR 2004

L57 170 S L56  
L58 0 S L57 AND L50  
L59 0 S L57 AND L47

FILE 'REGISTRY' ENTERED AT 10:53:29 ON 06 APR 2004

L60 STR L27  
L61 0 S L60 SAM SUB=L24  
L62 3476 S L17,L23  
L63 0 S L60 SAM SUB=L62  
L64 45 S L60 FUL SUB=L62  
SAV L64 KAM847E/A

FILE 'HCAPLUS' ENTERED AT 11:00:25 ON 06 APR 2004

L65 3 S L64

FILE 'REGISTRY' ENTERED AT 11:00:45 ON 06 APR 2004

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 11:00:56 ON 06 APR 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Apr 2004 VOL 140 ISS 15  
FILE LAST UPDATED: 5 Apr 2004 (20040405/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l65 all hitstr tot



L65 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN  
AN 2001:689112 HCAPLUS  
DN 136:70060  
ED Entered STN: 20 Sep 2001  
TI Synthesis and biological evaluation of vancomycin dimers with potent activity against vancomycin-resistant bacteria: target-accelerated combinatorial synthesis  
AU Nicolaou, K. C.; Hughes, Robert; Cho, Suk Young; Winssinger, Nicolas; Labischinski, Harald; Endermann, Rainer  
CS Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA  
SO Chemistry--A European Journal (2001), 7(17), 3824-3843  
CODEN: CEUJED; ISSN: 0947-6539  
PB Wiley-VCH Verlag GmbH  
DT Journal  
LA English  
CC 34-3 (Amino Acids, Peptides, and Proteins)  
Section cross-reference(s): 1, 33  
AB Based on the notion that dimerization and/or variation of amino acid 1 of vancomycin could potentially enhance biol. activity, a series of synthetic and chemical biol. studies were undertaken in order to discover potent antibacterial agents. We describe two ligation methods (disulfide formation and olefin metathesis) for dimerizing vancomycin derivs. and applications of target-accelerated combinatorial synthesis (e.g., combinatorial synthesis in the presence of vancomycin's target Ac2-L-Lys-D-Ala-D-Ala) to generate libraries of vancomycin dimers. Screening of these compound libraries led to the identification of a number of highly potent antibiotics effective against vancomycin-susceptible, vancomycin-intermediate resistant and, most significantly, vancomycin-resistant bacteria.  
ST target accelerated combinatorial synthesis vancomycin dimer library; ligation disulfide formation olefin metathesis vancomycin dimer synthesis; vancomycin dimer prepn antibacterial  
IT Peptides, preparation  
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation)  
(oligopeptides; synthesis and biol. evaluation of vancomycin dimers with potent activity against vancomycin-resistant bacteria, including target-accelerated combinatorial synthesis)  
IT Antibacterial agents  
Peptide library  
(synthesis and biol. evaluation of vancomycin dimers with potent activity against vancomycin-resistant bacteria, including target-accelerated combinatorial synthesis)  
IT Combinatorial chemistry  
(target-accelerated; synthesis and biol. evaluation of vancomycin dimers with potent activity against vancomycin-resistant bacteria, including target-accelerated combinatorial synthesis)  
IT 321361-75-5P 383185-24-8P 383185-26-0P 383185-28-2P 383185-30-6P  
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)  
(synthesis and biol. evaluation of vancomycin dimers with potent activity against vancomycin-resistant bacteria, including target-accelerated combinatorial synthesis)  
IT 1404-90-6DP, Vancomycin, dimeric derivs. 321361-73-3P 321361-77-7P 321361-81-3P 383185-34-0P 383185-37-3P 383383-25-3P  
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation)  
(synthesis and biol. evaluation of vancomycin dimers with potent activity against vancomycin-resistant bacteria, including target-accelerated combinatorial synthesis)

IT 1119-94-4, Dodecyltrimethylammonium bromide 19993-26-1 105149-26-6  
RL: CRG (Combinatorial reagent); RGT (Reagent); CMBI (Combinatorial study); RACT (Reactant or reagent)  
(synthesis and biol. evaluation of vancomycin dimers with potent activity against vancomycin-resistant bacteria, including target-accelerated combinatorial synthesis)

IT 383185-18-0 383185-20-4 383185-22-6  
RL: CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); RACT (Reactant or reagent)  
(synthesis and biol. evaluation of vancomycin dimers with potent activity against vancomycin-resistant bacteria, including target-accelerated combinatorial synthesis)

IT 321361-79-9P 321361-83-5P 321361-85-7P 321361-87-9P 321361-89-1P  
321361-91-5P 321361-95-9P 383183-13-9P 383183-14-0P 383183-15-1P  
383183-16-2P 383183-17-3P 383183-18-4P 383183-19-5P 383183-20-8P  
383183-21-9P 383183-22-0P 383183-23-1P 383183-24-2P 383183-25-3P  
383183-26-4P 383183-28-6P 383183-29-7P 383183-48-0P 383183-49-1P  
383183-50-4P 383183-51-5P 383183-52-6P 383183-53-7P 383183-54-8P  
383183-55-9P 383183-56-0P 383183-57-1P 383183-58-2P 383183-59-3P  
383183-60-6P 383183-61-7P 383183-62-8P 383183-63-9P 383183-64-0P  
383183-66-2P 383183-67-3P 383183-68-4P 383183-69-5P 383183-70-8P  
383183-83-3P 383183-84-4P 383183-85-5P 383183-86-6P 383183-87-7P  
383183-88-8P 383183-89-9P 383183-90-2P 383183-91-3P 383183-92-4P  
383183-93-5P 383183-94-6P 383183-95-7P 383183-96-8P 383183-99-1P  
383184-01-8P 383184-03-0P 383184-06-3P 383184-09-6P 383184-10-9P  
383184-11-0P 383184-13-2P 383184-15-4P 383184-17-6P 383184-21-2P  
383184-23-4P 383184-26-7P 383184-27-8P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(synthesis and biol. evaluation of vancomycin dimers with potent activity against vancomycin-resistant bacteria, including target-accelerated combinatorial synthesis)

IT 2127-03-9 321361-97-1 321361-99-3 321362-01-0 321362-03-2  
321362-05-4 321362-07-6 321362-09-8 321362-11-2 321362-13-4  
321362-17-8 383183-30-0 383183-31-1  
383183-32-2 383183-33-3 383183-34-4  
383183-35-5 383183-36-6 383183-37-7  
383183-38-8 383183-39-9 383183-40-2  
383183-41-3 383183-42-4 383183-43-5  
383183-44-6 383183-45-7 383183-46-8  
383183-71-9 383183-72-0 383183-73-1  
383183-74-2 383183-75-3 383183-76-4  
383183-77-5 383183-78-6 383183-79-7  
383183-80-0 383183-81-1 383183-82-2  
383184-29-0 383184-31-4 383184-33-6 383184-34-7 383184-36-9  
383184-39-2 383184-41-6 383184-43-8 383184-45-0 383184-47-2  
383184-48-3 383184-50-7 383184-53-0 383184-56-3 383184-58-5  
383184-60-9 383184-62-1 383184-65-4 383184-67-6 383184-70-1  
383184-72-3 383184-76-7 383184-79-0 383184-81-4 383184-85-8  
383184-87-0 383184-91-6 383184-95-0 383184-97-2  
383184-99-4 383185-04-4 383185-06-6  
383185-07-7 383185-09-9 383185-11-3  
383185-12-4 383185-32-8  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(synthesis and biol. evaluation of vancomycin dimers with potent activity against vancomycin-resistant bacteria, including target-accelerated combinatorial synthesis)

IT 383183-27-5P 383183-47-9P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(synthesis and biol. evaluation of vancomycin dimers with potent activity against vancomycin-resistant bacteria, including target-accelerated combinatorial synthesis)

RE.CNT 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD

## RE

- (1) Adamczyk, M; Bioorg Med Chem Lett 1999, V9, P2437 HCAPLUS
- (2) Albrecht, M; Chem Eur J 1999, V5, P48 HCAPLUS
- (3) Arimoto, H; Chem Commun 1999, P1361 HCAPLUS
- (4) Beauregard, D; Antimicrob Agents Chemother 1995, V39, P781
- (5) Berl, V; Eur J Org Chem 1999, P3089 HCAPLUS
- (6) Brady, P; J Chem Soc Perkin Trans 1 1997, P3237 HCAPLUS
- (7) Bush, K; Curr Opin Chem Biol 1997, V1, P169 HCAPLUS
- (8) Calama, M; Chem Commun 1998, P1021 HCAPLUS
- (9) Cooper, M; Chem Biol 1999, V6, P891 HCAPLUS
- (10) Cousins, G; Angew Chem 2001, V113, P437
- (11) Cousins, G; Angew Chem Int Ed 2001, V40, P423 HCAPLUS
- (12) Cousins, G; Chem Commun 1999, P1575 HCAPLUS
- (13) Cousins, G; Curr Opin Chem Biol 2000, V4, P270 HCAPLUS
- (14) Dougherty, T; Curr Opin Anti-Infect Invest Drugs 1999, V1, P18 HCAPLUS
- (15) Erlanson, D; Proc Natl Acad Sci 2000, V97, P9367 HCAPLUS
- (16) Furstner, A; Angew Chem 2000, V112, P3140
- (17) Furstner, A; Angew Chem Int Ed 2000, V39, P3012 HCAPLUS
- (18) Furstner, A; Top Organomet Chem 1998, V1, P37 HCAPLUS
- (19) Gerhard, U; J Am Chem Soc 1993, V115, P232 HCAPLUS
- (20) Grubbs, R; Tetrahedron 1998, V54, P4413 HCAPLUS
- (21) Hamilton, D; New J Chem 1998, V22, P1019 HCAPLUS
- (22) Hasenknopf, B; Angew Chem 1996, V108, P1987
- (23) Hasenknopf, B; Angew Chem Int Ed 1996, V35, P1838 HCAPLUS
- (24) Hasenknopf, B; J Am Chem Soc 1997, V119, P10956 HCAPLUS
- (25) Hioki, H; J Org Chem 1998, V63, P904 HCAPLUS
- (26) Hiramatsu, K; Drug Resist Updates 1998, V1, P135 HCAPLUS
- (27) Huc, I; Proc Natl Acad Sci 1997, V94, P2106 HCAPLUS
- (28) Jorgensen, T; Anal Chem 1998, V70, P4427 HCAPLUS
- (29) Jorgensen, T; J Chem Soc Perkin Trans 2 1999, P1859 HCAPLUS
- (30) Klekota, B; Tetrahedron Lett 1997, V38, P8639 HCAPLUS
- (31) Leclercq, R; N Engl J Med 1998, V319, P157
- (32) Lee, S; Tetrahedron Lett 1998, V39, P873 HCAPLUS
- (33) Lehn, J; Chem Eur J 1999, V5, P2455 HCAPLUS
- (34) Lehn, J; Science 2001, V291, P2331 HCAPLUS
- (35) Loll, P; Chem Biol 1998, V5, P293 HCAPLUS
- (36) Loll, P; J Am Chem Soc 1997, V119, P1516 HCAPLUS
- (37) Lynn, D; J Am Chem Soc 1996, V118, P784 HCAPLUS
- (38) Mackay, J; J Am Chem Soc 1994, V116, P4573 HCAPLUS
- (39) Mackay, J; J Am Chem Soc 1994, V116, P4581 HCAPLUS
- (40) Malabarba, T; Med Res Rev 1997, V17, P69
- (41) Maly, D; Proc Natl Acad Sci 2000, V97, P2419 HCAPLUS
- (42) Mammen, M; Angew Chem 1998, V110, P2908
- (43) Mammen, M; Angew Chem Int Ed 1998, V37, P2754
- (44) Mohr, B; Organometallics 1996, V15, P4317 HCAPLUS
- (45) Nawrocki, J; Rapid Commun Mass Spectrom 1996, V10, P1860 HCAPLUS
- (46) Nawrocki, J; Synlett 1998, P688
- (47) Nicolaou, K; Chem Eur J 2001, V7, P3798 HCAPLUS
- (48) Nieto, M; Biochem J 1971, V124, P845 HCAPLUS
- (49) Otto, S; J Am Chem Soc 2000, V122, P12063 HCAPLUS
- (50) Ramstorm, O; ChemBioChem 2000, V1, P41
- (51) Rao, J; J Am Chem Soc 1997, V119, P10286 HCAPLUS
- (52) Rao, J; J Am Chem Soc 2000, V122, P2698 HCAPLUS
- (53) Rao, J; Science 1998, V280, P708 HCAPLUS
- (54) Schmid, M; Curr Opin Chem Biol 1998, V2, P529 HCAPLUS
- (55) Schuster, M; Angew Chem 1997, V109, P2150
- (56) Schuster, M; Angew Chem Int Ed 1997, V36, P2036
- (57) Shuker, S; Science 1996, V274, P1531 HCAPLUS
- (58) Stack, D; EP 0801075 A1 1997 HCAPLUS
- (59) Staroske, T; Chem Eur J 2000, V6, P504 HCAPLUS
- (60) Staroske, T; Tetrahedron Lett 1998, V39, P4917 HCAPLUS
- (61) Sundram, U; J Am Chem Soc 1996, V118, P13107 HCAPLUS
- (62) Waltho, J; J Am Chem Soc 1989, V111, P2475 HCAPLUS

- (63) Westwell, B; Chem Commun 1999, P589  
(64) Wigger, M; Rapid Commun Mass Spectrom 1997, V11, P1749 HCAPLUS  
(65) Williams, D; Science 1998, V280, P711 HCAPLUS  
(66) Zhu, J; Expert Opin Ther Patents 1999, V9, P1005 HCAPLUS

IT 321362-17-8 383183-30-0 383183-31-1  
383183-32-2 383183-33-3 383183-34-4  
383183-35-5 383183-36-6 383183-37-7  
383183-38-8 383183-39-9 383183-40-2  
383183-41-3 383183-42-4 383183-43-5  
383183-44-6 383183-45-7 383183-46-8  
383183-71-9 383183-72-0 383183-73-1  
383183-74-2 383183-75-3 383183-76-4  
383183-77-5 383183-78-6 383183-79-7  
383183-80-0 383183-81-1 383183-82-2  
383184-95-0 383184-97-2 383184-99-4  
383185-04-4 383185-06-6 383185-07-7  
383185-09-9 383185-11-3 383185-12-4  
383185-32-8

RL: RCT (Reactant); RACT (Reactant or reagent)


(synthesis and biol. evaluation of vancomycin dimers with potent activity against vancomycin-resistant bacteria, including target-accelerated combinatorial synthesis)

RN 321362-17-8 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 383183-30-0 HCAPLUS


RN 585163-30-0 HCAPLOS  
 CN Vancomycin, N3''-[3-[4-(acetylthio)butoxy]phenyl]methyl)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 383183-31-1 HCAPLUS


CN Vancomycin, N3'''-[[3-[[5-(acetylthio)pentyl]oxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




PAGE 2-A

Cl




PAGE 2-B




RN 383183-32-2 HCAPLUS  
 CN Vancomycin, N3'''-[[3-[[6-(acetylthio)hexyl]oxy]phenyl]methyl] - (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 383183-33-3 HCAPLUS


CN Vancomycin, N3'''-[[3-[[10-(acetylthio)decyl]oxy]phenyl]methyl]- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl<sub>1</sub>

PAGE 2-B




RN 383183-34-4 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]-4-butoxyphenyl]methyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 383183-35-5 HCAPLUS


CN Vancomycin, N3'''-[[3-[4-(acetylthio)butoxy]-4-butoxyphenyl]methyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 383183-36-6 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]-4-(heptyloxy)phenyl]methyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B






PAGE 2-A

cl\_

PAGE 2-B




^RN 383183-37-7 HCAPLUS


Vancomycin, N3'''-[3-[4-(acetylthio)butoxy]-4-(heptyloxy)phenyl]methyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 383183-38-8 HCAPLUS


CN Vancomycin, N3''-[[3-[3-(acetylthio)propoxy]-4-(phenylmethoxy)phenyl]methyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 383183-39-9 HCAPLUS


CN Vancomycin, N3'''-[[3-[4-(acetylthio)butoxy]-4-(phenylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 383183-40-2 HCAPLUS


CN Vancomycin, N3'''-[3-[3-(acetylthio)propoxy]-4-[(4-chlorophenyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 383183-41-3 HCAPLUS

CN Vancomycin, N3''-[[3-[4-(acetylthio)butoxy]-4-[(4-chlorophenyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A






PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 383183-42-4 HCAPLUS


CN	Vancomycin,	N3'''-[4-[3-(acetylthio)propoxy]phenyl]methyl]-	(9CI)	(CA
	INDEX NAME)			

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl<sub>1</sub>

PAGE 2-B




RN 383183-43-5 HCAPLUS


CN Vancomycin, N3'''-[[4-[4-(acetylthio)butoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 383183-44-6 HCAPLUS


CN Vancomycin, N3''' - [[4-[[5-(acetylthio)pentyl]oxy]phenyl]methyl] - (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

c1\_

PAGE 2-B




RN 383183-45-7 HCAPLUS


CN Vancomycin, N3'''-[[4-[[6-(acetylthio)hexyl]oxy]phenyl]methyl]- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 383183-46-8 HCAPLUS

CN Vancomycin, N3'''-[[4-[[10-(acetylthio)decylloxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 383183-71-9 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-28-  
 [[[(carboxymethyl)amino]carbonyl]-28-decarboxy-49-de[4-methyl-2-  
 (methylamino)-1-oxopentyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383183-72-0 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-(aminoacetyl)-28-[[[(carboxymethyl)amino]carbonyl]-28-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383183-73-1 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-[(2R)-2-amino-1-oxopropyl]-28-[[[(carboxymethyl)amino]carbonyl]-28-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383183-74-2 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-(3-amino-1-oxopropyl)-28-[[[(carboxymethyl)amino]carbonyl]-28-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383183-75-3 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-28-  
 [[[(carboxymethyl)amino]carbonyl]-28-decarboxy-49-de[4-methyl-2-  
 (methylamino)-1-oxopentyl]-49-[(methylamino)acetyl]-(9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B






RN 383183-76-4 HCAPLUS


CN Vancomycin, N3''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-(4-amino-1-oxobutyl)-28-[[[(carboxymethyl)amino]carbonyl]-28-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383183-77-5 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-(7-amino-1-oxoheptyl)-28-[[[(carboxymethyl)amino]carbonyl]-28-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383183-78-6 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]-28-[[[(carboxymethyl)amino]carbonyl]-28-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 383183-79-7 HCAPLUS  
CN Vancomycin, N3''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-[(2S)-2-amino-3-methyl-1-oxobutyl]-28-[[[(carboxymethyl)amino]carbonyl]-28-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383183-80-0 HCAPLUS


Vancomycin, N3''' - [[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-[(2S)-2-amino-3-cyclohexyl-1-oxopropyl]-28-[[[(carboxymethyl)amino]carbonyl]-28-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383183-81-1 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-28-  
 [[(carboxymethyl)amino]carbonyl]-28-decarboxy-56-demethyl-, (51S)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B






RN 383183-82-2 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-[(2S)-2-amino-3-hydroxy-1-oxopropyl]-28-[[[(carboxymethyl)amino]carbonyl]-28-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383184-95-0 HCAPLUS


CN Vancomycin, N3''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-[(2S,3R)-2-amino-3-hydroxy-1-oxobutyl]-26-[[[(carboxymethyl)amino]carbonyl]-26-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383184-97-2 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-[(2S)-2-amino-4-(methylthio)-1-oxobutyl]-26-[[[(carboxymethyl)amino]carbonyl]-26-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 383184-99-4 HCAPLUS  
CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-[(2S)-2-amino-1-oxo-3-phenylpropyl]-26-[[[(carboxymethyl)amino]carbonyl]-26-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383185-04-4 HCAPLUS


Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-[(2S)-2-amino-3-(4-hydroxyphenyl)-1-oxopropyl]-26-[[[(carboxymethyl)amino]carbonyl]-26-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383185-06-6 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-[(2S)-2-amino-1-oxo-3-(2-thienyl)propyl]-26-[[[(carboxymethyl)amino]carbonyl]-26-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B






RN 383185-07-7 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-54-amino-26-  
[[[(carboxymethyl)amino]carbonyl]-26-decarboxy-53,56-didemethyl- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383185-09-9 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-26-  
 [[(carboxymethyl)amino]carbonyl]-26-decarboxy-49-de[4-methyl-2-  
 (methylamino)-1-oxopentyl]-49-[(2S)-2,6-diamino-1-oxohexyl]- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383185-11-3 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-54-  
 [(aminocarbonyl)amino]-26-[[[(carboxymethyl)amino]carbonyl]-26-decarboxy-  
 53,56-didemethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 383185-12-4 HCAPLUS  
 CN Vancomycin, N3''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-[(2S)-2-amino-4-(1,1-dimethylethoxy)-1,4-dioxobutyl]-26-[[[(carboxymethyl)amino]carbonyl]-26-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383185-32-8 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-54-(1,1-dimethylethoxy)-26-[[[(carboxymethyl)amino]carbonyl]-26-decarboxy-53,56-didemethyl-54-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B



L65 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2001:689110 HCAPLUS  
 DN 136:70059  
 ED Entered STN: 20 Sep 2001  
 TI Solid- and solution-phase synthesis of vancomycin and vancomycin analogues with activity against vancomycin-resistant bacteria  
 AU Nicolaou, K. C.; Cho, Suk Young; Hughes, Robert; Winssinger, Nicolas; Smethurst, Christian; Labischinski, Harald; Endermann, Rainer  
 CS Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA  
 SO Chemistry--A European Journal (2001), 7(17), 3798-3823  
 CODEN: CEUJED; ISSN: 0947-6539  
 PB Wiley-VCH Verlag GmbH  
 DT Journal  
 LA English  
 CC 34-3 (Amino Acids, Peptides, and Proteins)  
 Section cross-reference(s): 1, 33  
 AB Vancomycin, the prototypical member of the glycopeptide family of antibiotics, is a clin. used antibiotic employed against a variety of drug-resistant bacterial strains including methicillin-resistant *Staphylococcus aureus* (MRSA). The recent emergence of vancomycin

resistance, viewed as a growing threat to public health, prompted us to initiate a program aimed at restoring the potency of this important antibiotic through chemical manipulation of the vancomycin structure. We describe the development of synthetic technol. based on the design of a novel selenium safety catch linker, application of this technol. to a solid-phase semisynthesis of vancomycin, and the solid- and solution-phase synthesis of vancomycin libraries. Biol. evaluation of these compound libraries led to the identification of a number of in vitro highly potent antibacterial agents effective against vancomycin-resistant bacteria. In addition to aiding these investigations, the solid-phase chemical described herein is expected to enhance the power of combinatorial chemical and facilitate chemical biol. and medicinal chemical studies.

- ST vancomycin analog synthesis antibacterial; selenium safety catch linker  
solid phase synthesis vancomycin analog
- IT Solid phase synthesis  
(peptide; selenium safety catch linker in synthesis of vancomycin and  
vancomycin analogs with activity against vancomycin-resistant bacteria)
- IT Antibacterial agents  
Antibiotics  
Peptide library  
(synthesis of vancomycin and vancomycin analogs with activity against  
vancomycin-resistant bacteria)
- IT Glycopeptides  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL  
(Biological study); PREP (Preparation)  
(synthesis of vancomycin and vancomycin analogs with activity against  
vancomycin-resistant bacteria)
- IT 383183-30-0 383183-31-1 383183-32-2  
383183-33-3 383183-34-4 383183-35-5  
383183-36-6 383183-37-7 383183-38-8  
383183-39-9 383183-40-2 383183-41-3  
383183-45-7 383183-46-8 383183-76-4  
383424-20-2 383424-21-3 383424-22-4 383424-23-5 383424-24-6  
383424-25-7 383424-26-8 383424-27-9  
RL: PAC (Pharmacological activity); BIOL (Biological study)  
(synthesis of vancomycin and vancomycin analogs with activity against  
vancomycin-resistant bacteria)
- IT 321361-97-1P 321362-17-8P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant  
or reagent)  
(synthesis of vancomycin and vancomycin analogs with activity against  
vancomycin-resistant bacteria)
- IT 1404-90-6DP, Vancomycin, analogs 119728-56-2P 321361-99-3P  
321362-01-0P 321362-05-4P 321362-07-6P 321362-09-8P 321362-11-2P  
321362-13-4P 383183-42-4P 383183-43-5P  
383183-44-6P 383183-71-9P 383183-72-0P  
383183-74-2P 383183-75-3P 383183-78-6P  
383183-79-7P 383183-80-0P 383183-81-1P  
383183-82-2P 383184-29-0P 383184-31-4P 383184-33-6P  
383184-34-7P 383184-36-9P 383184-39-2P 383184-41-6P 383184-43-8P  
383184-45-0P 383184-47-2P 383184-53-0P 383184-56-3P 383184-58-5P  
383184-60-9P 383184-62-1P 383184-65-4P 383184-67-6P 383184-70-1P  
383184-72-3P 383184-76-7P 383184-79-0P 383184-81-4P 383184-85-8P  
383184-87-0P 383184-91-6P 383184-95-0P 383184-97-2P  
383184-99-4P 383185-04-4P 383185-06-6P  
383185-07-7P 383185-09-9P 383185-11-3P  
383185-12-4P 383185-32-8P 383423-61-8P 383423-62-9P  
383423-63-0P 383423-64-1P 383423-65-2P 383423-66-3P 383423-68-5P  
383423-69-6P 383423-70-9P 383423-71-0P 383424-16-6P 383424-17-7P  
383424-31-5P 383424-32-6P 383424-33-7P 383424-34-8P  
383424-35-9P 383424-36-0P 383424-37-1P 383424-38-2P 383424-39-3P  
383424-40-6P 383424-41-7P 383424-42-8P 383424-43-9P 383424-44-0P



383424-45-1P 383424-46-2P 383424-47-3P 383424-48-4P 383424-49-5P  
 383424-50-8P 383424-51-9P 383424-52-0P 383424-53-1P 383424-54-2P  
 383424-55-3P 383424-56-4P 383424-57-5P 383424-58-6P 383424-59-7P  
 383424-60-0P 383424-61-1P 383424-62-2P 383424-63-3P 383424-64-4P  
 383424-65-5P 383424-66-6P 383424-67-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL  
 (Biological study); PREP (Preparation)

(synthesis of vancomycin and vancomycin analogs with activity against  
 vancomycin-resistant bacteria)

IT 100-51-6, Benzenemethanol, reactions 100-83-4 103-72-0,  
 Phenylthioisocyanate 107-18-6, 2-Propen-1-ol, reactions 111-87-5,  
 1-Octanol, reactions 112-30-1, 1-Decanol 123-08-0,  
 4-Hydroxybenzaldehyde 139-85-5, 3,4-Dihydroxybenzaldehyde 507-09-5,  
 Thiolacetic acid, reactions 627-27-0, 3-Buten-1-ol 627-31-6,  
 1,3-Diiodopropane 821-09-0, 4-Penten-1-ol 821-41-0, 5-Hexen-1-ol  
 873-76-7 1404-93-9, Vancomycin hydrochloride 13019-22-2, 9-Decen-1-ol  
 14002-51-8, [1,1'-Biphenyl]-4-carbonyl chloride 17746-05-3, Undecanoyl  
 chloride 133754-40-2D, Selenohypobromous acid, resin-bound 221182-36-1  
 273736-70-2 383423-48-1 383423-49-2 383423-50-5 383423-51-6  
 383423-52-7 383423-53-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(synthesis of vancomycin and vancomycin analogs with activity against  
 vancomycin-resistant bacteria)

IT 1404-90-6P, Vancomycin 4049-39-2P 40359-32-8P 40663-68-1P  
 66488-78-6P 105534-98-3P 124201-59-8P 137916-69-9P 143231-97-4P  
 214847-86-6P 221182-45-2P 250290-69-8P 255047-42-8P 273736-58-6P  
 273736-62-2DP, resin-bound 273736-68-8DP, resin-bound 273736-69-9DP,  
 resin-bound 273736-71-3DP, resin-bound 273736-72-4DP, resin-bound  
 273736-73-5DP, resin-bound 273736-74-6P 273736-75-7P 383423-47-0DP,  
 resin-bound 383423-54-9DP, resin-bound 383423-55-0DP, resin-bound  
 383423-56-1DP, resin-bound 383423-57-2DP, resin-bound 383423-58-3DP,  
 resin-bound 383423-60-7DP, resin-bound 383423-72-1DP, resin-bound  
 383423-73-2DP, resin-bound 383423-74-3DP, resin-bound 383423-75-4DP,  
 resin-bound 383423-76-5DP, resin-bound 383423-77-6DP, resin-bound  
 383423-79-8P 383423-80-1P 383423-81-2P 383423-82-3P 383423-83-4P  
 383423-84-5P 383423-85-6P 383423-87-8P 383423-88-9P 383423-90-3P  
 383423-92-5P 383423-93-6P 383423-95-8P 383424-00-8P 383424-28-0P  
**383424-29-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(synthesis of vancomycin and vancomycin analogs with activity against  
 vancomycin-resistant bacteria)

IT 5447-02-9P 88036-81-1P 248588-29-6P 383423-86-7P 383423-89-0P  
 383423-91-4P 383423-94-7P 383423-96-9P 383423-97-0P 383423-98-1P  
 383423-99-2P 383424-01-9P 383424-02-0P 383424-03-1P 383424-04-2P  
 383424-05-3P 383424-06-4P 383424-07-5P 383424-08-6P 383424-09-7P  
 383424-10-0P 383424-11-1P 383424-12-2P 383424-13-3P 383424-14-4P  
 383424-15-5P **383424-30-4P** 383424-68-8P

RL: SPN (Synthetic preparation); PREP (Preparation)

(synthesis of vancomycin and vancomycin analogs with activity against  
 vancomycin-resistant bacteria)

RE.CNT 84 THERE ARE 84 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Allen, N; Antimicrob Agents Chemother 1997, V41, P66 HCAPLUS
- (2) Anon; Glycopeptide Antibiotics 1994
- (3) Atuegbu, A; Bioorg Med Chem 1996, V4, P1097 MEDLINE
- (4) Backes, B; Curr Opin Chem Biol 1997, V1, P86 HCAPLUS
- (5) Barna, J; J Am Chem Soc 1984, V106, P4895 HCAPLUS
- (6) Beauregard, D; Antimicrob Agents Chemother 1995, V39, P781 HCAPLUS
- (7) Boger, D; J Am Chem Soc 1999, V121, P3226 HCAPLUS
- (8) Booth, P; J Chem Soc Chem Commun 1987, P1694 HCAPLUS
- (9) Chen, S; J Am Chem Soc 1997, V119, P8724 HCAPLUS
- (10) Cristofaro, M; J Antibiot 1995, V48, P805 HCAPLUS

- (11) Cristofaro, M; J Antibiot 1995, V48, P805 HCAPLUS
- (12) Dougherty, T; Curr Opin Ami-Infect Invest Drugs 1999, V1, P18 HCAPLUS
- (13) Dragoli, D; J Comb Chem 1999, V1, P534 HCAPLUS
- (14) Evans, D; Angew Chem 1998, V110, P2864
- (15) Evans, D; Angew Chem 1998, V110, P2868
- (16) Evans, D; Angew Chem Int Ed 1998, V37, P2700 HCAPLUS
- (17) Evans, D; Angew Chem Int Ed 1998, V37, P2704 HCAPLUS
- (18) Felmingham, D; J Antimicrob Chemother 1993, V32, P663 MEDLINE
- (19) Ge, M; Science 1999, V284, P507 HCAPLUS
- (20) Gullier, M; Chem Rev 2000, V100, P2091
- (21) Hasan, A; Tetrahedron 1997, V53, P4247 HCAPLUS
- (22) Hiramatsu, K; Drug Resist Updates 1998, V1, P135 HCAPLUS
- (23) James, I; Tetrahedron 1999, V55, P4855 HCAPLUS
- (24) Kerns, R; J Am Chem Soc 2000, V122, P12608 HCAPLUS
- (25) Kosch, W; React Polym 1994, V22, P181 HCAPLUS
- (26) Leclercq, R; N Engl J Med 1988, V319, P157
- (27) Lee, K; Org Lett 1999, V1, P1859 HCAPLUS
- (28) Levine, J; Med Clin North Am 1987, V71, P1135 HCAPLUS
- (29) Levy, S; Sci Am 1998, P46 HCAPLUS
- (30) Nagarajan, R; J Antibiot 1988, V41, P1430 HCAPLUS
- (31) Nagarajan, R; J Antibiot 1989, V42, P63 HCAPLUS
- (32) Nagarajan, R; J Antibiot 1993, V46, P1181 HCAPLUS
- (33) Nagarajan, R; J Chem Soc Chem Commun 1998, P1306
- (34) Nicas, T; Antimicrob Agents Chemother 1989, V33, P1477 HCAPLUS
- (35) Nicolaou, K; Angew Chem 1997, V109, P2181
- (36) Nicolaou, K; Angew Chem 1998, V110, P2677
- (37) Nicolaou, K; Angew Chem 1998, V110, P2872
- (38) Nicolaou, K; Angew Chem 1998, V110, P2879
- (39) Nicolaou, K; Angew Chem 1998, V110, P2881
- (40) Nicolaou, K; Angew Chem 1999, V111, P2230
- (41) Nicolaou, K; Angew Chem 1999, V111, P253
- (42) Nicolaou, K; Angew Chem 2000, V112, P1126
- (43) Nicolaou, K; Angew Chem Int Ed 1997, V36, P2097 HCAPLUS
- (44) Nicolaou, K; Angew Chem Int Ed 1998, V37, P2534 HCAPLUS
- (45) Nicolaou, K; Angew Chem Int Ed 1998, V37, P2708 HCAPLUS
- (46) Nicolaou, K; Angew Chem Int Ed 1998, V37, P2714 HCAPLUS
- (47) Nicolaou, K; Angew Chem Int Ed 1998, V37, P2717 HCAPLUS
- (48) Nicolaou, K; Angew Chem Int Ed 1999, V38, P2096
- (49) Nicolaou, K; Angew Chem Int Ed 1999, V38, P240 HCAPLUS
- (50) Nicolaou, K; Angew Chem Int Ed 2000, V39, P1084 HCAPLUS
- (51) Nicolaou, K; Angew Chem Int Ed 2000, V39, P3823 HCAPLUS
- (52) Nicolaou, K; Chem Commun 1998, V18, P1947
- (53) Nicolaou, K; Chem Eur J 1999, V5, P2584 HCAPLUS
- (54) Nicolaou, K; Chem Eur J 1999, V5, P2602 HCAPLUS
- (55) Nicolaou, K; Chem Eur J 1999, V5, P2622 HCAPLUS
- (56) Nicolaou, K; Chem Eur J 1999, V5, P2648 HCAPLUS
- (57) Nicolaou, K; Chem Eur J 2001, V7, P3824 HCAPLUS
- (58) Nicolaou, K; J Am Chem Soc 1997, V119, P449 HCAPLUS
- (59) Nicolaou, K; J Am Chem Soc 1998, V120, P10814 HCAPLUS
- (60) Nicolaou, K; J Am Chem Soc 1998, V120, P5132 HCAPLUS
- (61) Nicolaou, K; Nature 1997, V387, P268 HCAPLUS
- (62) Overman, L; Angew Chem 1984, V96, P565 HCAPLUS
- (63) Overman, L; Angew Chem Int Ed 1984, V23, P579
- (64) Peterseim, M; React Polym 1993, V20, P189
- (65) Pillai, V; Synthesis 1980, P1 HCAPLUS
- (66) Ruhland, T; J Org Chem 1998, V63, P9204 HCAPLUS
- (67) Seitz, O; Angew Chem 1995, V107, P901
- (68) Seitz, O; Angew Chem Int Ed 1995, V34, P803 HCAPLUS
- (69) Seitz, O; J Org Chem 1997, V62, P813 HCAPLUS
- (70) Smith, T; N Engl J Med 1999, V340, P493 HCAPLUS
- (71) Solenberg, P; Chem Biol 1997, V4, P195 HCAPLUS
- (72) Somma, S; Antimicrob Agents Chemother 1984, V26, P917 HCAPLUS
- (73) Sundram, U; J Org Chem 1995, V60, P1102 HCAPLUS

- (74) Thompson, C; J Am Chem Soc 1999, V121, P1237 HCAPLUS  
 (75) Thompson, L; J Org Chem 1998, V63, P2066 HCAPLUS  
 (76) Walsh, C; Chem Biol 1996, V3, P21 HCAPLUS  
 (77) Williams, D; Angew Chem 1999, V111, P1264  
 (78) Williams, D; Angew Chem Int Ed 1999, V38, P1172  
 (79) Williams, D; J Am Chem Soc 1983, V105, P1332 HCAPLUS  
 (80) Wright, G; Acc Chem Res 1992, V25, P468 HCAPLUS  
 (81) Xiao, X; J Org Chem 1997, V62, P6029 HCAPLUS  
 (82) Xu, R; J Am Chem Soc 1999, V121, P2898  
 (83) Yao, R; Drugs Pharm Sci 1994, V63, P1 HCAPLUS  
 (84) Zhu, J; Exp Opin Ther Patents 1999, V9, P1005 HCAPLUS

IT 383183-30-0 383183-31-1 383183-32-2  
 383183-33-3 383183-34-4 383183-35-5  
 383183-36-6 383183-37-7 383183-38-8  
 383183-39-9 383183-40-2 383183-41-3  
 383183-45-7 383183-46-8 383183-76-4


RL: PAC (Pharmacological activity); BIOL (Biological study)  
 (synthesis of vancomycin and vancomycin analogs with activity against  
 vancomycin-resistant bacteria)

RN 383183-30-0 HCAPLUS


CN Vancomycin, N3'''-[[3-[4-(acetylthio)butoxy]phenyl]methyl]- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 383183-31-1 HCAPLUS


CN Vancomycin, N3'''-[[3-[[5-(acetylthio)pentyl]oxy]phenyl]methyl]- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 383183-32-2 HCAPLUS


CN Vancomycin, N3'''-[[3-[[6-(acetylthio)hexyl]oxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 383183-33-3 HCAPLUS

CN Vancomycin, N3'''-[3-[[10-(acetylthio)decyl]oxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A






PAGE 1-B



PAGE 2-A

c1\_

PAGE 2-B




RN 383183-34-4 HCAPLUS


CN Vancomycin, N3''' - [[3-[3-(acetylthio)propoxy]-4-butoxyphenyl]methyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl<sub>1</sub>

PAGE 2-B




RN 383183-35-5 HCAPLUS


CN Vancomycin, N3'''-[[3-[4-(acetylthio)butoxy]-4-butoxyphenyl]methyl] - (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 383183-36-6 HCAPLUS


383183-36-8    NCAPL03  
 Vancomycin, N3'''-[ [3-[3-(acetylthio)propoxy]-4-(heptyloxy)phenyl]methyl]-  
 (9CI)    (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl<sub>2</sub>

PAGE 2-B




RN 383183-37-7 HCAPLUS


CN Vancomycin, N3'''-[[3-[4-(acetylthio)butoxy]-4-(heptyloxy)phenyl]methyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 383183-38-8 HCAPLUS

CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]-4-(phenylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 383183-39-9 HCAPLUS


CN Vancomycin, N3'''-[[3-[4-(acetylthio)butoxy]-4-(phenylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 383183-40-2 HCAPLUS


CN Vancomycin, N3''-[3-[3-(acetylthio)propoxy]-4-[(4-chlorophenyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 383183-41-3 HCAPLUS


CN Vancomycin, N3' '-[[3-[4-(acetylthio)butoxy]-4-[(4-chlorophenyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 383183-45-7 HCAPLUS


CN Vancomycin, N3'''-[[4-[[6-(acetylthio)hexyl]oxy]phenyl]methyl]- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B






RN 383183-46-8 HCAPLUS


CN Vancomycin, N3'''-[[4-[[10-(acetylthio)decyloxy]phenyl]methyl]- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 383183-76-4 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-(4-amino-1-oxobutyl)-28-[[[(carboxymethyl)amino]carbonyl]-28-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B



IT 321362-17-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)


(synthesis of vancomycin and vancomycin analogs with activity against vancomycin-resistant bacteria)

RN 321362-17-8 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B



IT 383183-42-4P 383183-43-5P 383183-44-6P  
 383183-71-9P 383183-72-0P 383183-74-2P  
 383183-75-3P 383183-78-6P 383183-79-7P  
 383183-80-0P 383183-81-1P 383183-82-2P  
 383184-95-0P 383184-97-2P 383184-99-4P  
 383185-04-4P 383185-06-6P 383185-07-7P  
 383185-09-9P 383185-11-3P 383185-12-4P  
 383185-32-8P 383424-31-5P 383424-32-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL  
 (Biological study); PREP (Preparation)  
 (synthesis of vancomycin and vancomycin analogs with activity against  
 vancomycin-resistant bacteria)

RN 383183-42-4 HCAPLUS


CN Vancomycin, N3'''-[[4-[3-(acetylthio)propoxy]phenyl]methyl]- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 383183-43-5 HCAPLUS


CN Vancomycin, N3'''-[[4-[4-(acetylthio)butoxy]phenyl]methyl]- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B






RN 383183-44-6 HCAPLUS


CN Vancomycin, N3'''-[[4-[[5-(acetylthio)pentyl]oxy]phenyl]methyl]- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 383183-71-9 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-28-  
 [[[(carboxymethyl)amino]carbonyl]-28-decarboxy-49-de[4-methyl-2-  
 (methylamino)-1-oxopentyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383183-72-0 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-(aminoacetyl)-28-[[[(carboxymethyl)amino]carbonyl]-28-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383183-74-2 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-(3-amino-1-oxopropyl)-28-[[[(carboxymethyl)amino]carbonyl]-28-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383183-75-3 HCAPLUS


CN Vancomycin, N3''' - [[3-[3-(acetylthio)propoxy]phenyl]methyl]-28-  
 [[(carboxymethyl)amino]carbonyl]-28-decarboxy-49-de[4-methyl-2-  
 (methylamino)-1-oxopentyl]-49-[(methylamino)acetyl]- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383183-78-6 HCAPLUS


CN Vancomycin, N3'''-[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]-28-[[[(carboxymethyl)amino]carbonyl]-28-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B







RN 383183-79-7 HCAPLUS  
CN Vancomycin, N3''-[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-[(2S)-2-amino-3-methyl-1-oxobutyl]-28-[[[(carboxymethyl)amino]carbonyl]-28-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B






PAGE 1-B



PAGE 2-B




RN 383183-81-1 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-28-  
 [[[(carboxymethyl)amino]carbonyl]-28-decarboxy-56-demethyl-, (51S) - (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383183-82-2 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-[(2S)-2-amino-3-hydroxy-1-oxopropyl]-28-[[[(carboxymethyl)amino]carbonyl]-28-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383184-95-0 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-[(2S,3R)-2-amino-3-hydroxy-1-oxobutyl]-26-[[[(carboxymethyl)amino]carbonyl]-26-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383184-97-2 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-[(2S)-2-amino-4-(methylthio)-1-oxobutyl]-26-[[[(carboxymethyl)amino]carbonyl]-26-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B






RN 383184-99-4 HCAPLUS


Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-[(2S)-2-amino-1-oxo-3-phenylpropyl]-26-[[ (carboxymethyl) amino]carbonyl]-26-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383185-04-4 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-[(2S)-2-amino-3-(4-hydroxyphenyl)-1-oxopropyl]-26-[[[(carboxymethyl)amino]carbonyl]-26-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383185-06-6 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-[(2S)-2-amino-1-oxo-3-(2-thienyl)propyl]-26-[[[(carboxymethyl)amino]carbonyl]-26-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-B




RN 383185-07-7 HCAPLUS  
CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-54-amino-26-  
[[[(carboxymethyl)amino]carbonyl]-26-decarboxy-53,56-didemethyl- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383185-09-9 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-26-  
 [[[(carboxymethyl)amino]carbonyl]-26-decarboxy-49-de[4-methyl-2-  
 (methylamino)-1-oxopentyl]-49-[(2S)-2,6-diamino-1-oxohexyl]- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383185-11-3 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-54-  
 [(aminocarbonyl)amino]-26-[[[(carboxymethyl)amino]carbonyl]-26-decarboxy-  
 53,56-didemethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B







RN 383185-12-4 HCAPLUS  
CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-[(2S)-2-amino-4-(1,1-dimethylethoxy)-1,4-dioxobutyl]-26-[[[(carboxymethyl)amino]carbonyl]-26-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383185-32-8 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-54-(1,1-dimethylethoxy)-26-[[[(carboxymethyl)amino]carbonyl]-26-decarboxy-53,56-didemethyl-54-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383424-31-5 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-[(2S)-2-amino-1-oxopropyl]-26-[[[(carboxymethyl)amino]carbonyl]-26-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 383424-32-6 HCAPLUS


Vancomycin, N3'--[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-(6-amino-1-oxohexyl)-26-[[ (carboxymethyl) amino] carbonyl]-26-decarboxy-49-de[4-methyl-2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B



IT 383424-29-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(synthesis of vancomycin and vancomycin analogs with activity against vancomycin-resistant bacteria)

RN 383424-29-1 HCAPLUS


CN Vancomycin, N3'''-[3-[3-(acetylthio)propoxy]phenyl]methyl]-56-[(1,1-dimethylethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl<sub>2</sub>

PAGE 2-B



IT 383424-30-4P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(synthesis of vancomycin and vancomycin analogs with activity against  
vancomycin-resistant bacteria)

RN 383424-30-4 HCAPLUS

CN Vancomycin, N3''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]-49-de[4-methyl-  
2-(methylamino)-1-oxopentyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A






PAGE 1-B



PAGE 2-A


Cl

PAGE 2-B



L65 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2000:818978 HCAPLUS  
 DN 134:116215  
 ED Entered STN: 22 Nov 2000  
 TI Target-accelerated combinatorial synthesis and discovery of highly potent antibiotics effective against vancomycin-resistant bacteria  
 AU Nicolaou, K. C.; Hughes, Robert; Cho, Suk Young; Winssinger, Nicolas; Smethurst, Christian; Labischinski, Harald; Endermann, Rainer  
 CS Skaggs Inst. Chemical Biology, Scripps Res. Inst., La Jolla, CA, 92037, USA  
 SO Angewandte Chemie, International Edition (2000), 39(21), 3823-3828  
 CODEN: ACIEF5; ISSN: 1433-7851  
 PB Wiley-VCH Verlag GmbH  
 DT Journal  
 LA English  
 CC 34-3 (Amino Acids, Peptides, and Proteins)  
 Section cross-reference(s): 1  
 OS CASREACT 134:116215  
 GI

↓  
*Oct 2000*



AB The authors report the application of direct target-accelerated combinatorial synthesis (TACS) of vancomycin dimers for the identification of ligands with the highest affinity for vancomycin's receptor, D-Ala-D-Ala. For example, solid- and solution-phase combinatorial chemical

were

used to synthesize a library of vancomycin substrates, from which a set of monomers I [ $n = 2-4$ ;  $X = \text{SCOMe}$ ,  $\text{CH:CH}_2$ ;  $R = \text{H}$ ,  $\text{D}-(\text{NMe})\text{Leu}$ ,  $\beta\text{-Ala}$ ,  $\text{L-Asn}$ , etc.] were chosen for the target-accelerated dimerization step. I ( $X = \text{SCOMe}$ ) was subjected to ligation by disulfide bond formation and I ( $X = \text{CH:CH}_2$ ) was subjected to ligation by olefin metathesis in both the absence and presence of vancomycin's targets,  $\text{Ac-D-Ala-D-Ala-OH}$  and  $\text{Ac-Lys(Ac)-D-Ala-D-Ala-OH}$ , for which vancomycin has the greatest affinity. Here, a strong target-induced rate acceleration was observed in the presence

of these targets. Thus, target-accelerated combinatorial synthesis was performed, and from this library, several olefin metathesis dimers of I [n = 2-4; R = H, D-(NMe)Leu,  $\beta$ -Ala, Asn] and disulfide dimers of I [n = 2,3; R = D-(NMe)Leu] were identified, and these were, then, individually synthesized from their resp. monomers. Antibacterial activity for these dimers were reported; of them, some have potent activities against vancomycin-resistant enterococci (VRE) and vancomycin intermediate susceptible *Staphylococcus aureus* (VISA) that rival or exceed the most active compds. known today for these bacterial strains.

- ST target accelerated combinatorial synthesis vancomycin dimer library; olefin metathesis dimer vancomycin synthesis; disulfide vancomycin dimer synthesis; vancomycin dimer antibiotic activity resistant bacteria VRE VISA
- IT Peptides, preparation  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(cyclic; target-accelerated combinatorial synthesis of vancomycin dimers as highly potent antibiotics effective against vancomycin-resistant bacteria)
- IT Antibiotics  
(macrolide; target-accelerated combinatorial synthesis of vancomycin dimers as highly potent antibiotics effective against vancomycin-resistant bacteria)
- IT Antibiotic resistance  
Combinatorial library  
(target-accelerated combinatorial synthesis of vancomycin dimers as highly potent antibiotics effective against vancomycin-resistant bacteria)
- IT Combinatorial chemistry  
(target-accelerated; preparation of vancomycin substrates for the target-accelerated combinatorial synthesis of vancomycin dimers)
- IT 19993-26-1 24570-39-6  
RL: NUU (Other use, unclassified); USES (Uses)  
(as the "target" in the target-accelerated combinatorial synthesis of vancomycin dimers)
- IT 321361-97-1P 321361-99-3P 321362-01-0P 321362-03-2P 321362-05-4P  
321362-07-6P 321362-09-8P 321362-11-2P 321362-13-4P  
**321362-15-6P 321362-17-8P**  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of vancomycin substrates for the target-accelerated combinatorial synthesis of vancomycin dimers)
- IT 60-54-8, Tetracycline 1404-90-6, Vancomycin  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(target-accelerated combinatorial synthesis of vancomycin dimers as highly potent antibiotics effective against vancomycin-resistant bacteria)
- IT 321361-73-3P 321361-75-5P 321361-77-7P 321361-79-9P 321361-81-3P  
321361-83-5P 321361-85-7P 321361-87-9P 321361-89-1P 321361-91-5P  
321361-93-7P 321361-95-9P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(target-accelerated combinatorial synthesis of vancomycin dimers as highly potent antibiotics effective against vancomycin-resistant bacteria)

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Adamczyk, M; Bioorg Med Chem Lett 1999, V9, P2437 HCAPLUS
- (2) Anon; Curr Opin Chem Biol 2000, V4, P243
- (3) Arimoto, H; Chem Commun 1999, P1361 HCAPLUS

- (4) Beauregard, D; Antimicrob Agents Chemother 1994, V116, P781
- (5) Clark, T; J Am Chem Soc 1995, V117, P12364 HCAPLUS
- (6) Ge, M; Science 1999, V284, P507 HCAPLUS
- (7) Gerhard, U; J Am Chem Soc 1993, V115, P232 HCAPLUS
- (8) Grubbs, R; Tetrahedron 1998, V54, P4413 HCAPLUS
- (9) Hanakai, H; Jpn J Antibiot 1998, V51, P272
- (10) Hanaki, H; J Antimicrob Chemother 1998, V42, P199 HCAPLUS
- (11) Hiramatsu, K; Drug Resist Updates 1998, V1, P135 HCAPLUS
- (12) Huc, I; Proc Natl Acad Sci USA 1997, V94, P2106 HCAPLUS
- (13) Leclercq, R; N Engl J Med 1988, V319, P157 MEDLINE
- (14) Lee, D; Nature 1997, V390, P591 HCAPLUS
- (15) Lehn, J; Chem Eur J 1999, V5, P2455 HCAPLUS
- (16) Loll, P; J Am Chem Soc 1997, V119, P1516 HCAPLUS
- (17) Mackay, J; J Am Chem Soc 1994, V116, P4573 HCAPLUS
- (18) Maly, D; Proc Natl Acad Sci USA 2000, V97, P2419 HCAPLUS
- (19) Mammen, M; Angew Chem 1998, V110, P2908
- (20) Mammen, M; Angew Chem Int Ed 1998, V37, P2754
- (21) Nicolaou, K; Angew Chem 1999, V111, P2230
- (22) Nicolaou, K; Angew Chem Int Ed 1999, V38, P2096
- (23) Rao, J; J Am Chem Soc 1997, V119, P10286 HCAPLUS
- (24) Rao, J; Science 1998, V280, P708 HCAPLUS
- (25) Shuker, S; Science 1996, V274, P1531 HCAPLUS
- (26) Stack, D; EP 0801075 A1 1997 HCAPLUS
- (27) Staroske, T; Chem Eur J 2000, V6, P504 HCAPLUS
- (28) Staroske, T; Tetrahedron Lett 1998, V39, P4917 HCAPLUS
- (29) Sundram, U; J Am Chem Soc 1996, V118, P13107 HCAPLUS
- (30) Walsh, C; Chem Biol 1996, V3, P21 HCAPLUS
- (31) Williams, D; Angew Chem 1999, V111, P1264
- (32) Williams, D; Angew Chem Int Ed 1999, V38, P1173 HCAPLUS
- (33) Williams, D; Science 1998, V280, P711 HCAPLUS
- (34) Williams, W; J Am Chem Soc 1983, V105, P1332
- (35) Xu, R; J Am Chem Soc 1999, V121, P4898 HCAPLUS
- (36) Zhu, J; Exp Opin Ther Patents 1999, V9, P1005 HCAPLUS

IT 321362-15-6P 321362-17-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)


(preparation of vancomycin substrates for the target-accelerated  
combinatorial synthesis of vancomycin dimers)

RN 321362-15-6 HCAPLUS


CN Vancomycin, N3'''-[[3-[2-(acetylthio)ethoxy]phenyl]methyl]- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B




RN 321362-17-8 HCAPLUS


CN Vancomycin, N3'''-[[3-[3-(acetylthio)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B



=>